X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet   (NTPH)

Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 727.7
Mkt Cap Rs m 120,899
Vol '000 3.3
P/E X 15.4
P/CF X 94.0
EPS (TTM) Rs 47.1
% ch % 1.5
No. of shares m 166.15
% ch week % 9.8
% ch 1-mth % -10.5
% ch 12-mth % -26.6
52 week H/L Rs 1,062.0/637.4
(As on Oct 16, 2018 11:09:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs156358361505877 
Low Rs47134197330424 
Sales per share (Unadj.) Rs162.2163.3168.1210.6223.4 
Earnings per share (Unadj.) Rs17.319.019.122.931.1 
Diluted earnings per shareRs2.93.23.64.36.2 
Cash flow per share (Unadj.) Rs24.324.724.230.040.3 
Dividends per share (Unadj.) Rs2.002.003.004.005.00 
Adj. dividends per shareRs0.340.340.560.761.00 
Dividend yield (eoy) %2.00.81.11.00.8 
Book value per share (Unadj.) Rs108.6125.2152.0170.1219.5 
Adj. book value per shareRs18.421.228.532.143.7 
Shares outstanding (eoy) m28.1528.1531.1531.3733.07 
Bonus/Rights/Conversions  ESOP-PPESOPPA 
Price / Sales ratio x0.61.51.72.02.9 
Avg P/E ratio x5.912.914.618.220.9 
P/CF ratio (eoy) x4.210.011.513.916.1 
Price / Book Value ratio x0.92.01.82.53.0 
Dividend payout %11.610.515.717.516.1 
Avg Mkt Cap Rs m2,8576,9258,69113,10021,504 
No. of employees `000NANANANANA 
Total wages/salary Rs m5896648011,0231,128 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
NATCO PHARMA INCOME DATA
Net Sales Rs m4,5674,5975,2376,6057,389 
Other income Rs m464691124167 
Total revenues Rs m4,6134,6435,3296,7297,556 
Gross profit Rs m9138891,0941,4991,793 
Depreciation Rs m197159159221304 
Interest Rs m130125230263366 
Profit before tax Rs m6326517951,1391,290 
Minority Interest Rs m816116046 
Prior Period Items Rs m-160000 
Extraordinary Inc (Exp) Rs m000-1160 
Tax Rs m137132211364309 
Profit after tax Rs m4875355967191,027 
Gross profit margin %20.019.320.922.724.3 
Effective tax rate %21.620.326.532.023.9 
Net profit margin %10.711.611.410.913.9 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m1,9232,4702,9283,3053,681 
Current liabilities Rs m1,6461,9342,5943,4493,123 
Net working cap to sales %6.111.76.4-2.27.6 
Current ratio x1.21.31.11.01.2 
Inventory Days Days6281778189 
Debtors Days Days4656667259 
Net fixed assets Rs m3,0143,4614,8406,8867,685 
Share capital Rs m282282312314331 
"Free" reserves Rs m2,5363,0054,1384,7686,670 
Net worth Rs m3,0573,5244,7365,3357,259 
Long term debt Rs m5221,2541,3411,378955 
Total assets Rs m5,5437,0739,05210,80411,957 
Interest coverage x5.86.24.55.34.5 
Debt to equity ratio x0.20.40.30.30.1 
Sales to assets ratio x0.80.60.60.60.6 
Return on assets %11.19.39.19.111.7 
Return on equity %15.915.212.613.514.2 
Return on capital %21.116.617.120.120.7 
Exports to sales %21.128.334.242.739.4 
Imports to sales %4.17.07.47.45.7 
Exports (fob) Rs m9641,3011,7902,8172,908 
Imports (cif) Rs m187323388486421 
Fx inflow Rs m9821,3992,1783,2053,445 
Fx outflow Rs m209446570628703 
Net fx Rs m7749531,6082,5772,743 
NATCO PHARMA CASH FLOW
From Operations Rs m 774 370 649 612 1,440 
From Investments Rs m -609 -888 -1,269 -1,071 -1,089 
From Financial Activity Rs m -342 771 628 263 -353 
Net Cashflow Rs m -176 253 8 -196 -1 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   TTK HEALTHCARE  SHASUN PHARMA  LUPIN LTD  WYETH LTD  SANOFI INDIA  

Compare NATCO PHARMA With:   TTK HEALTHCARE  SHASUN PHARMA  LUPIN LTD  WYETH LTD  SANOFI INDIA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Realty & Consumer Durables Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is up 0.4%.

Views on news

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS